Central Obesity
Conditions
Brief summary
The purpose of this study is to compare the effects of ultrasound cavitation and whole-body electromyostimulation (WB-EMS) on inflammatory markers in individuals with central obesity.
Detailed description
Sixty individuals with central obesity were recruited from private clinics. And underwent a screening process to determine their eligibility based on the inclusion and exclusion criteria. Eligible participants were informed about the study details, procedures, potential risks, and benefits before obtaining written informed consent
Interventions
DEVICEcavitation, whole body electromyostimulation
The duration of the study was set for 12 weeks. Assessments were meticulously conducted at both the baseline and the conclusion of the study period to evaluate outcomes across the different groups.
Sponsors
Cairo University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Adults aged 18-50 years. * Individuals diagnosed with central obesity, defined as a waist circumference greater than 102 cm in men and 88 cm in women. * Participants with a stable body weight for at least three months prior to the study. * No engagement in regular physical activity or weight loss programs in the past six months. * Willingness to adhere to study protocols and attend all scheduled sessions.
Exclusion criteria
* Individuals with chronic diseases other than obesity-related conditions, such as cardiovascular disease, diabetes, or severe hypertension. * Pregnant or lactating women. * Individuals with implanted electronic devices (e.g., pacemakers). * Participants with dermatological conditions or skin infections in the treatment area. * Individuals undergoing medication that may affect fat metabolism or inflammatory markers.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Inflammatory Markers | 3 Monthes | Measurement of changes in levels of Tumor Necrosis Factor-alpha (TNF-alpha), and Interleukin-6 (IL-6) using ELISA (Enzyme-Linked Immunosorbent Assay) kits. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Waist Circumference | 3 Monthes | Will be measured at the level of the iliac crest using a standard measuring tape to assess changes in central adiposity. |
| Body Weight | 3 Monthes | Standard clinical scales to measure body weight at each visit to track changes over the study period. |
| Body Mass Index (BMI) | 3 Monthes | Will be calculated using measured height and weight (kg/m²) to observe changes in overall body mass classification. |
Countries
Egypt
Outcome results
None listed